Stockscreener 앱 받기
153.56
0.43%
-0.825
전일 마감가:
$154.38
열려 있는:
$154.38
하루 거래량:
74,341
Relative Volume:
0.46
시가총액:
$6.13B
수익:
-
순이익/손실:
$-77.61M
주가수익비율:
-66.82
EPS:
-2.2979
순현금흐름:
-
1주 성능:
-0.50%
1개월 성능:
-10.19%
6개월 성능:
+37.58%
1년 성능:
+151.55%
1일 변동 폭
$151.89
$155.29
1주일 범위
$151.89
$160.24
52주 변동 폭
$56.10
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Compare BLTE vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
153.29 | 6.17B | 0 | -77.61M | 0 | -2.2979 |
VRTX
Vertex Pharmaceuticals Inc
|
425.18 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
720.92 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.26 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.64 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.76 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-26 | 개시 | BofA Securities | Buy |
| 2026-01-06 | 개시 | Morgan Stanley | Overweight |
| 2025-12-02 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-11-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-11-20 | 개시 | Mizuho | Neutral |
| 2023-12-14 | 개시 | Maxim Group | Buy |
| 2023-07-28 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-26 | 개시 | SVB Securities | Outperform |
| 2022-08-01 | 개시 | H.C. Wainwright | Buy |
| 2022-07-01 | 개시 | The Benchmark Company | Buy |
모두보기
Belite Bio Inc Adr 주식(BLTE)의 최신 뉴스
Belite Bio chief scientific officer Nathan Mata sells $155,635 in shares - Investing.com
Belite Bio (NASDAQ: BLTE) CSO pre-planned sale of 1,000 ADS - Stock Titan
Belite Bio CSO Nathan Mata sells $155,777 in shares By Investing.com - Investing.com South Africa
Belite Bio (BLTE) CSO pre-planned sale of 1,000 ADS around $160 - Stock Titan
Belite Bio (BLTE) CSO sells 1,000 ADS in planned trades - Stock Titan
Belite Bio (BLTE) Initiates Rolling NDA Submission to FDA for Tinlarebant in STGD1 - Yahoo Finance
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Dry Age-Related Macular Degeneration Pipeline Grows as 70+ Pharma Companies Advance Novel Therapies for Vision Loss, Finds DelveInsight | Belite Bio, Stealth BioTherapeutics, Ocugen, Alkeus - Barchart
Belite Bio (NASDAQ:BLTE) Insider Nathan Mata Sells 1,000 Shares - MarketBeat
(BLTE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Belite Bio (NASDAQ: BLTE) CSO sells 1,000 ADS under 10b5-1 plan - Stock Titan
Belite bio CSO Nathan Mata sells $159,162 in shares - Investing.com
Belite bio CSO Nathan Mata sells $159,162 in shares By Investing.com - Investing.com India
Belite Bio (BLTE) CSO sells 1,000 ADS in planned open-market trades - Stock Titan
A Look At Belite Bio (BLTE) Valuation As Tinlarebant NDA Submission Progresses - Sahm
Belite Bio (NASDAQ:BLTE) Insider Sells $162,640.00 in Stock - MarketBeat
Belite Bio chief scientific officer Nathan Mata sells $162,641 in shares - Investing.com India
Belite Bio chief scientific officer Nathan Mata sells $162,641 in shares By Investing.com - Investing.com South Africa
Belite Bio (NASDAQ: BLTE) CSO sells 1,000 ADS under Rule 10b5-1 plan - Stock Titan
Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor ConferenceSlideshow - Seeking Alpha
Belite Bio Shares Tinlarebant Phase III Stargardt Data, FDA Rolling Submission at DB Conference - MarketBeat
Transcript : Belite Bio, Inc Presents at Deutsche Bank ADR Virtual Investor Conference, Apr-28-2026 09 - marketscreener.com
Belite Bio (NASDAQ:BLTE) Insider Sells $159,560.00 in Stock - MarketBeat
Belite Bio chief scientific officer Nathan Mata sells $159,555 in stock - Investing.com India
Belite Bio (BLTE) CSO sells 1,000 ADS under Rule 10b5-1 plan - Stock Titan
Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit - The Manila Times
Belite Bio CSO Nathan Mata sells $166,283 in shares By Investing.com - Investing.com Australia
Belite Bio CSO Nathan Mata sells $166,283 in shares - Investing.com
Belite Bio (BLTE) CSO sells 1,000 ADS in Rule 10b5-1 trades - Stock Titan
Belite Bio CSO Nathan Mata sells $170,384 in shares By Investing.com - Investing.com South Africa
Belite Bio CSO Nathan Mata sells $170,384 in shares - Investing.com
BELITE BIO (BLTE) CEO gains 10,000 shares from vested RSUs - Stock Titan
[Form 4] BELITE BIO, INC Insider Trading Activity - Stock Titan
Belite Bio (BLTE) CFO RSUs vest into 10,000 ordinary shares - Stock Titan
Belite Bio to Participate in Four Upcoming Investor Conferences - markets.businessinsider.com
Four Belite Bio conference appearances are set from April 28 to May 26 - Stock Titan
Belite Bio chief scientific officer sells $166,000 in shares By Investing.com - Investing.com Canada
Belite Bio chief scientific officer sells $166,000 in shares - Investing.com
Belite Bio (NASDAQ: BLTE) CSO pre-planned sale of 1,000 ADS disclosed - Stock Titan
Buy Initiation on Tinlarebant Developer: First-Mover Stargardt Opportunity Drives DCF-Based $200 Target Amid Key Late-Stage Catalysts and Risks - TipRanks
Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th - marketscreener.com
Belite Bio (NASDAQ:BLTE) Receives Buy Rating from HC Wainwright - MarketBeat
Belite Bio begins rolling NDA submission for Stargardt treatment By Investing.com - Investing.com India
Belite Bio CSO Nathan Mata sells $163,594 in shares By Investing.com - Investing.com Canada
Belite Bio CSO Nathan Mata sells $163,594 in shares - Investing.com
Belite Bio begins rolling NDA submission for Stargardt treatment - Investing.com
Belite Bio Inc Adr (BLTE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Belite Bio Inc Adr 주식 (BLTE) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| MATA NATHAN L. | Chief Scientific Officer |
May 01 '26 |
Sale |
155.78 |
1,000 |
155,778 |
3,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 30 '26 |
Sale |
156.97 |
1,000 |
156,973 |
4,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 29 '26 |
Sale |
155.82 |
1,000 |
155,817 |
5,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 28 '26 |
Sale |
159.16 |
1,000 |
159,162 |
6,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 27 '26 |
Sale |
162.64 |
1,000 |
162,641 |
7,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 24 '26 |
Sale |
159.56 |
1,000 |
159,556 |
8,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 23 '26 |
Sale |
166.28 |
1,000 |
166,284 |
9,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 22 '26 |
Sale |
170.38 |
1,000 |
170,384 |
10,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 21 '26 |
Sale |
166.00 |
1,000 |
166,000 |
11,666 |
| MATA NATHAN L. | Chief Scientific Officer |
Apr 20 '26 |
Sale |
163.59 |
1,000 |
163,595 |
12,666 |
0.78%
3.01%
자본화:
|
볼륨(24시간):